SCHEMBL953899

SCHEMBL953899

CC(C)(C)OC(=O)NC1CCN(C(=O)OCc2ccccc2)C1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.59
CTSL P07711 1/20 0.54
CTSB P07858 1/20 0.54
CTSK P43235 1/20 0.54
SMN1; SMN2 Q16637 3/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
KMT2A Q03164 2/20 0.53
CYP2C9 P11712 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
USP30 Q70CQ3 3/20 0.53
HTT P42858 1/20 0.52
PDE4B Q07343 1/20 0.51
CYP2C19 P33261 1/20 0.51
MEN1 O00255 1/20 0.51
F13A1 P00488 2/20 0.49
TGM2 P21980 2/20 0.49
TGM1 P22735 2/20 0.49
KCNA3 P22001 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1971844 1.00 HSD11B1 (0.59) HSD11B1CTSLCTSBCTSKSMN1; SMN2
SCHEMBL1775260 1.00 HSD11B1 (0.59) HSD11B1CTSLCTSBCTSKSMN1; SMN2
SCHEMBL2063483 0.94 USP30 (0.58) HSD11B1CTSLCTSBCTSKSMN1; SMN2
SCHEMBL2063481 0.94 USP30 (0.58) HSD11B1CTSLCTSBCTSKSMN1; SMN2
SCHEMBL6128873 0.94 USP30 (0.58) HSD11B1CTSLCTSBCTSKSMN1; SMN2
SCHEMBL951538 0.93 KMT2A (0.59) HSD11B1SMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL24705979 0.93 HSD11B1 (0.52) HSD11B1CTSLCTSBCTSKSMN1; SMN2
SCHEMBL28882375 0.93 HSD11B1 (0.52) HSD11B1CTSLCTSBCTSKSMN1; SMN2
SCHEMBL1564482 0.93 USP30 (0.55) HSD11B1CTSLCTSBCTSKSMN1; SMN2
SCHEMBL4703578 0.93 USP30 (0.55) HSD11B1CTSLCTSBCTSKSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426420-B2 Heterocyclic pyrazole-carboxamidesas P2Y12 antagonists SANOFI (FR) 2013-04-23 US disclosed
EP-2238128-B1 HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS SANOFI SA (FR) 2012-08-22 EP disclosed
US-20110021537-A1 HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS SANOFI-AVENTIS (FR) 2011-01-27 US disclosed
EP-2238128-A2 HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS Sanofi-Aventis (FR) 2010-10-13 EP disclosed
US-20100056497-A1 AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD (JP) 2010-03-04 US disclosed
US-20100056497-A1 AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD (JP) 2010-03-04 US disclosed
US-20100056497-A1 AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD (JP) 2010-03-04 US disclosed
EP-2119702-A1 AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2009-11-18 EP disclosed
EP-2119702-A1 AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2009-11-18 EP disclosed
WO-2009080226-A2 HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS SANOFIS-AVENTIS (FR) 2009-07-02 WO disclosed
EP-1698626-A1 AMIDOPYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed
WO-2005115977-A1 PYRROLIDINE DERIVATIVES AS CB1-RECEPTOR ANTAGONISTS TANABE SEIYAKU CO., LTD. (JP) 2005-12-08 WO disclosed
EP-1311501-B1 ANTITHROMBOTIC AGENTS LILLY CO ELI (US) 2005-11-02 EP disclosed
US-6924296-B2 Antithrombotic agents ELI LILLY AND COMPANY (US) 2005-08-02 US disclosed
EP-0828754-B1 DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE PFIZER (US) 2005-02-02 EP disclosed
US-20040010017-A1 Antithrombotic agents ELI LILLY AND COMPANY 2004-01-15 US disclosed
US-5936089-A PIPERIDINE DERIVATIVES; BONE DISORDERS; OBESITY; AGING; CACHEXIA ASSOCIATED WITH AIDS AND CANCER PFIZER INC (US) 1999-08-10 US disclosed
EP-0828754-A1 DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE PFIZER INC. (US) 1998-03-18 EP disclosed
WO-1996038471-A1 DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE PFIZER INC. (US) 1996-12-05 WO disclosed
WO-1996035713-A1 DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE PFIZER, INC. (US) 1996-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021537-A1 HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS P2RY1, P2RY12, P2RY11 HSD11B1 4093/4885CTSL 2634/4885CTSB 2044/4885
US-20040010017-A1 Antithrombotic agents SERPINC1, TFPI, F11 HSD11B1 476/4885CTSL 687/4885CTSB 1593/4885
US-20100056497-A1 AMIDE DERIVATIVE REN, AGTR1, AGTR2 HSD11B1 42/4885CTSL 1269/4885CTSB 326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.